A comparative study of cromolyn sodium gel 4% and pimecrolimus cream 1% anti pruritis effects on end stage renal failure patients undergoing dialysis in Ahwaz Imam Khomeini hospital in 2011

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107095069N3

Enrollment

Registered

2011-07-15

Start date

2011-04-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease. End stage renal disease

Interventions

Intervention 1: Cromolyn Sodium gel 4%, 40 gram twice a day for 8 weeks after dialysis in first intervention group. Intervention 2: Pimecrolimus cream 1%, 40 gram twice a day for 8 weeks after dialysi

Treatment - Drugs

Cromolyn Sodium gel 4%, 40 gram twice a day for 8 weeks after dialysis in first intervention group

Pimecrolimus cream 1%, 40 gram twice a day for 8 weeks after dialysis in second intervention group

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: known case of chronic renal failure, aged between 18 and 60 years old, not using of antihistamines or other anti-pruritus drugs during last 3 months. Exclusion criteria:the presence of other known pruritic diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pruritus. Timepoint: before intervention and every week for eight weeks. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Moosavian

Gachsaran Islamic Azad University

info@iaug.ac.ir+98 74 2333 4607

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026